StockData
Grace Therapeutics, Inc. logo

Grace Therapeutics, Inc. (GRCE) stock

GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$1.72−0.03 (-1.71%)

Close on Nov 17, 2026Market cap $36.18MP/E –Yield –

Grace Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Grace Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$23.91M. For fiscal 2026 it was -$11.08M. The highest annual figure on record is -$11.08M in fiscal 2026.

Annual operating income

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$11.08M–
FY2025Mar 31, 2025-$16.68M–
FY2024Mar 31, 2024-$12.85M–
FY2023Mar 31, 2023-$52.16M–
FY2022Mar 31, 2022-$15.59M–
FY2021Mar 31, 2021-$16.42M–
FY2020Mar 31, 2020-$24.44M–
FY2019Mar 31, 2019-$34.41M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026-$15.92M–
Q4 FY2026CQ1 2026Mar 31, 2026-$3.01M–
Q3 FY2026CQ4 2025Dec 31, 2025-$2.45M–
Q2 FY2026CQ3 2025Sep 30, 2025-$2.53M–
Q1 FY2026CQ2 2025Jun 30, 2025-$3.09M–
Q4 FY2025CQ1 2025Mar 31, 2025-$3.18M–
Q3 FY2025CQ4 2024Dec 31, 2024-$3.70M–
Q2 FY2025CQ3 2024Sep 30, 2024-$4.83M–
Q1 FY2025CQ2 2024Jun 30, 2024-$4.96M–
Q4 FY2024CQ1 2024Mar 31, 2024-$3.26M–
Q3 FY2024CQ4 2023Dec 31, 2023-$3.04M–
Q2 FY2024CQ3 2023Sep 30, 2023-$2.09M–
Q1 FY2024CQ2 2023Jun 30, 2023-$4.45M–
Q4 FY2023CQ1 2023Mar 31, 2023-$38.07M–
Q3 FY2023CQ4 2022Dec 31, 2022-$4.25M–
Q2 FY2023CQ3 2022Sep 30, 2022-$5.11M–
Q1 FY2023CQ2 2022Jun 30, 2022-$4.73M–
Q4 FY2022CQ1 2022Mar 31, 2022-$4.40M–
Q3 FY2022CQ4 2021Dec 31, 2021-$4.47M–
Q2 FY2022CQ3 2021Sep 30, 2021-$3.57M–
Q1 FY2022CQ2 2021Jun 30, 2021-$3.15M–
Q4 FY2021CQ1 2021Mar 31, 2021-$2.30M–
Q3 FY2021CQ4 2020Dec 31, 2020-$1.96M–
Q2 FY2021CQ3 2020Sep 30, 2020-$8.03M–
Q1 FY2021CQ2 2020Jun 30, 2020-$4.12M–
Q4 FY2020CQ1 2020Mar 31, 2020-$4.03M–
Q3 FY2020CQ4 2019Dec 31, 2019-$6.15M–
Q2 FY2020CQ3 2019Sep 30, 2019-$6.26M–
Q1 FY2020CQ2 2019Jun 30, 2019-$8.01M–

More Grace Therapeutics figures

See a number that looks wrong?